Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC).

Jens  Bedke

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; MSD; Novartis; Roche

Speakers' Bureau - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD; Novartis; Pfizer; Roche

Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)

Axel Stuart  Merseburger

Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda

Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology

Speakers' Bureau - Ipsen

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen-Cilag (Inst); Novartis (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen-Cilag

Yohann  Loriot

Honoraria - Pfizer; Sanofi

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen

Daniel  Castellano

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi

Research Funding - Janssen Oncology (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche

Ernest  Choy

Honoraria - Abbvie; Lilly; Merck Serono; Novartis; ObsEva; Pfizer; Radialogica; Regeneron; Roche/Genentech; Sanofi; SynAct Pharma

Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche/Genentech; Sanofi/Regeneron

Speakers' Bureau - Bristol-Myers Squibb; Janssen; Lilly; Novartis; Pfizer; Regeneron; Roche; Sanofi; UCB

Research Funding - Bio-Cancer Treatment International (Inst); Biogen (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)

Ignacio  Duran

Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen

Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Roche/Genentech

Jonathan E.  Rosenberg

Stock and Other Ownership Interests  - Illumina

Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico

Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)

Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche

Daniel Peter  Petrylak

Stock and Other Ownership Interests  - Bellicum Pharmaceuticals; TYME

Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma

Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Expert Testimony - Celgene; sanofi

Robert  Dreicer

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai; Genentech/Roche; Janssen Oncology; Modra Pharmaceuticals; Novartis; Orion; Pfizer; Seattle Genetics/Astellas; Vizuri

Research Funding - BioClin Therapeutics (Inst); Genentech (Inst); Janssen Oncology (Inst); Merck (Inst); Seagen (Inst)

Jose Luis  Perez-Gracia

Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Pierre Fabre; Roche; Seagen

Speakers' Bureau - Bristol-Myers Squibb; Eisai; MSD; Roche

Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte (Inst); Janssen (Inst); MSD (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche

Jean H.  Hoffman-Censits

No Relationships to Disclose

Michiel Simon  Van Der Heijden

Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche

Viraj  Degaonkar

Employment - Roche/Genentech

Stock and Other Ownership Interests  - Roche/Genentech

Lars  Thiebach

Employment - Roche Pharma AG

Stock and Other Ownership Interests  - F. Hoffmann LaRoche

Sabine  de Ducla

Employment - Celgene (I); Roche

Stock and Other Ownership Interests  - Roche; Roche (I)

Travel, Accommodations, Expenses - Roche; Roche (I)

Simon  Fear

Employment - Roche

Thomas  Powles

Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen

Research Funding - AstraZeneca/MedImmune; Roche/Genentech

Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech

Cora N.  Sternberg

Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Ipsen; Janssen; Pfizer; Sanofi

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Incyte; Ipsen; Medscape; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; UroToday

Research Funding - Aragon Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Myovant Sciences (Inst); Nektar (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)